BioNTech

Plans to Establish an mRNA Production Facility in Singapore!

  BioNTech Plans to Establish an mRNA Production Facility in Singapore! BioNTech said today it plans to set up a regional manufacturing facility in Singapore for vaccines based on messenger RNA technology (mRNA) to expand its production network. The biotech firm, backed by the Singapore Economic Development Board, will set up a manufacturing facility in Southeast Asia to respond to the growing global supply of mRNA-based vaccines. The Germany-based company established an US headquarters in Cambridge, Massachusetts in 2020. BioNTech BNTX (NasdaqGS) $193.74 +10.02(+5.46%) CEO and Co-Founder Uğur Şahin stated the following in his statement on the subject: "Having more than one nodes in our production network is an important strategic step in developing our global footprint and capabilities."

BioNTech said today it plans to set up a regional manufacturing facility in Singapore for vaccines

Production disruptions have seriously slowed the spread of Covid-19 vaccines. For this reason, many governments are trying to increase local vaccine production to secure access to supplies. Company, which plans to open its Singapore office in 2021, anticipates the production facility to be operational by 2023. With this planning, the company is considering to provide close to 80 jobs in Singapore. BioNTech has not made any statements about how many doses of mRNA-based vaccine the production site can produce.  

Source: finance.yahoo.com

 

You may also be interested in:

 

Intel Stock -Latest Status in Intel Stock Movements